December 16th, 2020

Dear Valued Patient,

We are writing to provide the latest update regarding the potential for near-term supply interruptions of multiple doses of NATPARA® (parathyroid hormone) for Injection that may impact U.S. patients receiving NATPARA through the Special Use Program (SUP). While we work with urgency to avoid any supply interruptions for patients receiving NATPARA through the SUP, our priority is to ensure that you and your prescriber are prepared in the event of an actual supply interruption. Given the fluid nature of the situation, we could have additional information available as soon as the week of December 21, 2020.

If you are receiving NATPARA 100-mcg or NATPARA 75-mcg, please see the following time-sensitive information regarding the immediate actions you must take. If you are receiving other doses of NATPARA, there’s nothing you need to do at this time. However, supply status updates for all other NATPARA doses are also included in this letter.

*IMMEDIATE ACTION REQUIRED FOR PATIENTS RECEIVING NATPARA 75-MCG OR NATPARA 100-MCG*

If you have not yet contacted your prescribing physician to determine the best treatment plan for you, please contact him/her as soon as possible. Since our update during the week of November 16, we are now preparing for a potential near-term supply interruption of NATPARA 75-mcg, in addition to the anticipated supply interruption of NATPARA 100-mcg. Based on our current assessments, we are anticipating supply interruptions for NATPARA 100-mcg as early as January 2, 2021, as well as for NATPARA 75-mcg, as early as mid-January.

Based on your prescriber’s independent medical judgement, your revised treatment plan may require a new prescription. Please ensure you work closely with your prescribing physician on any changes to your treatment plan, including the potential for a new prescription.

**Please note that if you are currently receiving NATPARA 100-mcg or NATPARA 75-mcg and you have not received an updated prescription, or if your prescriber has provided a modified dose for NATPARA 100-mcg that includes the 75-mcg dose of NATPARA, please contact your physician as soon as possible. For patients receiving NATPARA 100-mcg, we would need to receive an updated prescription form from your physician by December 22, 2020 and if you are a patient receiving NATPARA 75-mcg, we would need to receive an updated prescription form by January 8, 2021 in order to continue to ship medication to you. Updated prescription forms not received by these dates will result in disruption in shipments to you.**

However, if your physician has already submitted an updated prescription form in anticipation of a potential supply interruption, and that updated prescription does not include the 75-mcg dose of NATPARA, there’s nothing more you need to do. Your Takeda OnePath® Patient Support Manager will provide you with the shipment timing information for your updated prescription.

Patient safety is Takeda’s main priority and, as a patient enrolled in the Special Use Program who is receiving NATPARA 75-mcg or NATPARA 100-mcg, we are alerting you and your prescribing physician...
that any potential interruption or reduction in the daily dose of NATPARA can cause a sharp decrease in blood calcium levels (severe hypocalcemia) which can be dangerous. It is important for you to work closely with your healthcare provider for important medical recommendations, including frequent monitoring of your blood calcium levels and close titration of active vitamin D and calcium supplements if you stop or alter your dose as a result of this supply interruption to avoid hypocalcemia.

**Update Regarding NATPARA 25-mcg and 50-mcg:**
At this time, we do not expect SUP-enrolled patients who are receiving NATPARA 25-mcg or NATPARA 50-mcg to be impacted by near-term supply interruptions. However, we are closely monitoring all NATPARA doses based on the supply demands of the Special Use Program. We are committed to supply continuity and will provide another update on all NATPARA doses by mid-January. We have also communicated to physicians who have prescribed NATPARA 25-mcg or NATPARA 50-mcg that there is nothing they need to do at this time.

As a patient who is receiving NATPARA through the Special Use Program, we want to remind you that each NATPARA cartridge under the Special Use Program (single dose use) is intended for one use only, and that used cartridges with remaining product are to be returned to Takeda in accordance with the Special Use Program (single dose use) instructions. Non-compliance with the rules under the Special Use Program (single dose use) could result in termination of your ability to receive NATPARA product through the program.

OnePath will continue to work closely with your prescribing physician to support your treatment plan. If you have any immediate questions or concerns, please contact your Takeda OnePath® Patient Support Manager at 866-888-0660. Patient Support Managers are available Monday through Friday 8:30 AM – 8:00 PM ET.

Enclosed for your reference is the full NATPARA Prescribing Information and Medication Guide. For additional medical information, please contact your healthcare provider.

We recognize the important medical need that NATPARA fills for patients like you who are living with chronic hypoparathyroidism. As we have communicated previously, this is a fluid situation and we continue to work with urgency, and with US regulatory authority oversight, to avoid supply disruptions for patients receiving NATPARA through the SUP. We could have updated information regarding NATPARA 100-mcg and NATPARA 75-mcg as soon as the week of December 21, 2020 and will keep you updated as soon as new information is available. We appreciate your patience as we work to address these issues.

Sincerely,

Cheryl Schwartz  
Head of U.S. Rare Disease Business Unit

Daniel McNamara  
Head of U.S. Patient Services
What is NATPARA® (parathyroid hormone) for Injection?

- NATPARA is a prescription parathyroid hormone used with calcium and vitamin D to control low blood calcium (hypocalcemia) in people with low parathyroid hormone blood levels (hypoparathyroidism).
- NATPARA is only for people who do not respond well to treatment with calcium and active forms of vitamin D alone, because it may increase the possible risk of bone cancer (osteosarcoma).
- NATPARA was not studied in people with hypoparathyroidism caused by calcium-sensing receptor mutations.
- NATPARA was not studied in people who get sudden hypoparathyroidism after surgery.
- It is not known if NATPARA is safe and effective for children 18 years of age and younger. NATPARA should not be used in children and young adults whose bones are still growing.

Important Safety Information

What is the most important information I should know about NATPARA?

Warning: Possible bone cancer (osteosarcoma).

- During animal drug testing, NATPARA caused some rats to develop a bone cancer called osteosarcoma. It is not known if people who take NATPARA will have a higher chance of getting osteosarcoma. Tell your doctor right away if you have pain in any areas of your body that does not go away, or any new or unusual lumps or swelling under your skin that is tender to touch.

- NATPARA is only available through the NATPARA Risk Evaluation and Mitigation Strategy (REMS) Program. The purpose of the NATPARA REMS program is to inform patients about the potential risk of osteosarcoma associated with the use of NATPARA. For more information about this REMS program, call 1-855-NATPARA (628-7272) or go to www.NATPARAREMS.com.

NATPARA may cause other serious side effects, including:

High blood calcium (hypercalcemia)

- NATPARA can cause some people to have a higher blood calcium level than normal.
  1. Your doctor should check your blood calcium before you start and during your treatment with NATPARA.
  2. Tell your doctor if you have nausea, vomiting, constipation, low energy, or muscle weakness. These may be signs that you have too much calcium in your blood.

Low blood calcium (hypocalcemia)

- People who stop using or miss a dose of NATPARA may have an increased risk of severe low blood calcium levels.
- Tell your doctor if you have tingling of your lips, tongue, fingers and feet, twitching of face muscles, cramping of feet and hands, seizures, depression, or have problems thinking or remembering.

Who should not use NATPARA?

- Do not use NATPARA if you are allergic to parathyroid hormone or any of the ingredients in NATPARA.

What should I tell my healthcare provider before using NATPARA?

- Before you start using NATPARA, tell your doctor about all of your medical conditions. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of NATPARA?

- NATPARA may cause serious side effects like allergic (hypersensitivity) reaction, including anaphylaxis. Tell
your healthcare provider or get emergency medical help right away if you have any of the following symptoms of an allergic reaction:

- swelling of your face, lips, mouth, or tongue
- breathing problems
- fainting, dizziness, feeling lightheaded (low blood pressure)
- fast heartbeat
- itching
- rash
- hives

**The most common side effects of NATPARA include:** tingling, tickling, or burning feeling of the skin, low or high blood calcium, headache, nausea, reduced sense of touch or sensation, diarrhea, vomiting, pain in joints, too much calcium in urine, and pain in limbs.

**Enclosure:** NATPARA Full Prescribing Information

NATPARA® is a registered trademark of Shire-NPS Pharmaceuticals, Inc., a Takeda company. OnePath® is a registered trademark of Shire Human Genetic Therapies, Inc., a Takeda company. Copyright© 2020 Takeda Pharmaceutical Company Limited, 300 Shire Way, Lexington, MA 02421. All rights reserved. 1-800-828-2088. TAKEDA and the Takeda logo are registered trademarks of Takeda or its affiliates.